In this issue:
Durvalumab improves PFS in stage III NSCLC
HER2 mutations in lung adenocarcinomas
PD-1 vs PD-L1 inhibitors: similar toxicity and efficacy profiles
Nintedanib + pemetrexed/cisplatin shows promise in MPM
Evaluating nivolumab efficacy by ctDNA analysis
Dacomitinib for first-line SOC in EGFR-mutant NSCLC?
A low-cost predictive model identifies early lung cancer
CT lung screening encourages smoking cessation
Lorlatinib active in advanced ALK + or ROS1+ NSCLC
LMWH enoxaparin contraindicated as a tumour-inhibiting agent
Please login below to download this issue (PDF)